This article needs additional citations for verification. (August 2014) (Learn how and when to remove this template message)
This article includes a list of references, but its sources remain unclear because it has insufficient inline citations. (August 2014) (Learn how and when to remove this template message)
A molecular assay, Trofile was developed by Monogram Biosciences for use in HIV treatment. The assay's purpose is to identify the tropism of an individual patient's HIV strain – R5, X4, or a combination of these known as dual/mixed (D/M). The results show whether the patient is infected with virus that enters cells using the R5 co-receptor, the X4 co-receptor, or both (dual/mixed).
Patients with strains of HIV that prefer the R5 receptor tend to remain healthy longer than those with the strains that prefer X4. However, over the course of the disease, a patient's viral population may undergo a "tropism switch" from R5 to X4.
- Whitcomb, JM; Huang, W; Fransen, S; et al. (2007). "Development and characterization of a novel single-cycle recombinant virus assay to determine human immunodeficiency virus type 1 coreceptor tropism". Antimicrob Agents Chemother. 51 (2): 566–575.
- TrofileAssay.com Monogram Biosciences' Trofile assay website
- Four Studies Affirm Significance Of Monogram's Trofile™ HIV Co-Receptor Tropism Assay from Medical News Today, August 14, 2006
- Monogram Provides Update On Trofile™ Assay from Medical News Today, March 2, 2007
- Scientific Data Highlights Pivotal Role Of Monogram's Molecular Diagnostics In Development And Use Of New HIV Treatments from Medical News Today, March 7, 2007
|This molecular or cell biology article is a stub. You can help Wikipedia by expanding it.|